Home   >  

Classified by application

All Products

Signaling Pathways

Research Areas

Nature products

Antibodies

Peptides

Catalysts

Impurities

Intermediate

Raw Materials

Angiogenesis/Protein Tyrosine Kinase

Chemical Structure Cat. No. Product Name CAS No.
SU16F Chemical Structure
BCP46277 SU16F 251356-45-3
SU16F is a potent and selective platelet-derived growth factor receptor ß (PDGFRß) inhibitor.
AZD4205 Chemical Structure
BCP46221 AZD4205 2091134-35-7
AZD4205 is a highly potent JAK1-selective kinase inhibitor with excellent preclinical pharmacokinetics with potential for further clinical development. JAK1 is part of the JAK1/signal transducer and activator of transcription (STAT) axis, which plays an important role in tumour escape from EGFR-targeted treatment.
Ningetinib Chemical Structure
BCP46143 Ningetinib 1394820-69-9
Ningetinib is a novel tyrosine kinase inhibitor, targeted at c-Met, Axl, VEGFR-2, Mer and Flt3.
Ifidancitinib Chemical Structure
BCP46085 Ifidancitinib 1236667-40-5
Ifidancitinib is a Janus kinase inhibitor.
MAX-40279 hemiadipate Chemical Structure
BCP46003 MAX-40279 hemiadipate 2388506-44-1
MAX-40279 hemiadipate is a dual and potent inhibitor of FLT3 kinase and FGFR kinase.
MAX-40279 Chemical Structure
BCP46002 MAX-40279 2070931-57-4
MAX-40279 is an orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) and FMS-like tyrosine kinase 3 (FLT3; CD135; STK1; FLK2), with potential antineoplastic activity.
Ritlecitinib tosylate Chemical Structure
BCP45991 Ritlecitinib tosylate 2192215-81-7
Ritlecitinib, also known as PF-06651600, is a potent and selective JAK3 inhibitor.
Deuruxolitinib phosphate Chemical Structure
BCP45990 Deuruxolitinib phosphate 2147706-60-1
Deuruxolitinib(CTP-543), an oral inhibitor of Janus kinases JAK1 and JAK2, as a potential treatment for alopecia areata.
JAK-IN-5 Chemical Structure
BCP45656 JAK-IN-5 2096999-92-5
JAK-IN-5 is an inhibitor of JAK.
Tyk2-IN-5 Chemical Structure
BCP45577 Tyk2-IN-5 1797432-62-2
Tyk2-IN-5 is a highly potent, selective and orally active Tyk2 inhibitor and targets the JH2 domain, with a Ki of 0.086 nM for Tyk2 JH2 and an IC50 of 25 nM for IFNα.
123下一页末页共 833 条记录 1 / 84 页 
0086-13720134139